NextGen and Kemp Ink Protein Co-Marketing Pact | GenomeWeb
NEW YORK (GenomeWeb News) — NextGen and Kemp Biotechnologies will co-market their fee-for-service offerings, NextGen said today.
 
UK-based NextGen is a so-called “gene-to-protein” company, whereas Kemp provides expertise in cell culture, protein expression, and protein purification services.
 
Under the agreement, NextGen will offer Kemp’s pure proteins for pre-clinical research.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.